Literature DB >> 17198088

Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells.

Ann Leen1, Maheshika Ratnayake, Aaron Foster, Kenneth Heym, Nabil Ahmed, Cliona M Rooney, Stephen Gottschalk.   

Abstract

Mature dendritic cells (DCs) are potent antigen presenting cells (APCs) that have been used in vaccine studies and adoptive immunotherapy protocols. For many clinical studies DCs are derived from monocytes in the presence of cytokines, which are expensive and often unavailable for clinical use. Here we describe a cytokine independent method for the differentiation of monocytes into APCs for the reactivation of antigen-specific memory T cells from both healthy donors and cancer patients. Contact activation of monocytes resulted in secretion of proinflammatory cytokines, such as IL-8, and increased cell surface expression of costimulatory molecules. To determine if activated monocytes (actMo) like DC can reactivate antigen-specific CTL, they were transduced with adenoviral vectors encoding the subdominant Epstein Barr virus antigens, latent membrane proteins (LMP) 1 and 2, which are expressed in Epstein Barr virus-positive malignancies. Stimulation of peripheral blood mononuclear cells with LMP1- and LMP2-expressing actMo activated LMP1- and LMP2-specific T cells, which could be further expanded with LMP1 or LMP2 expressing lymphoblastoid cell lines. The use of actMo as APCs simplifies the production/manufacture of antigen-specific T cells for clinical trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17198088     DOI: 10.1097/01.cji.0000211325.30525.84

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  15 in total

1.  Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.

Authors:  Catherine M Bollard; Stephen Gottschalk; M Helen Huls; Ann M Leen; Adrian P Gee; Cliona M Rooney
Journal:  Cytotherapy       Date:  2011-03-01       Impact factor: 5.414

2.  Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein-Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.

Authors:  Patrick J Hanley; Donald R Shaffer; Conrad R Y Cruz; Stephanie Ku; Benjamin Tzou; Hao Liu; Gail Demmler-Harrison; Helen E Heslop; Clio M Rooney; Stephen Gottschalk; Catherine M Bollard
Journal:  Cytotherapy       Date:  2011-05-04       Impact factor: 5.414

3.  Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.

Authors:  Uluhan Sili; Ann M Leen; Juan F Vera; Adrian P Gee; Helen Huls; Helen E Heslop; Catherine M Bollard; Cliona M Rooney
Journal:  Cytotherapy       Date:  2012-01       Impact factor: 5.414

Review 4.  Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation.

Authors:  Ann M Leen; Tamara Tripic; Cliona M Rooney
Journal:  Expert Opin Biol Ther       Date:  2010-03       Impact factor: 4.388

5.  Transient detection of E1-containing adenovirus in saliva after the delivery of a first-generation adenoviral vector to human parotid gland.

Authors:  Changyu Zheng; Nikolay P Nikolov; Ilias Alevizos; Ana P Cotrim; Shuying Liu; Linda McCullagh; John A Chiorini; Gabor G Illei; Bruce J Baum
Journal:  J Gene Med       Date:  2010-01       Impact factor: 4.565

6.  Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.

Authors:  Ann M Leen; Anne Christin; Gary D Myers; Hao Liu; Conrad R Cruz; Patrick J Hanley; Alana A Kennedy-Nasser; Kathryn S Leung; Adrian P Gee; Robert A Krance; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard
Journal:  Blood       Date:  2009-08-21       Impact factor: 22.113

7.  Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.

Authors:  Chrystal U Louis; Karin Straathof; Catherine M Bollard; Claudia Gerken; M Helen Huls; M Victoria Gresik; Meng-Fen Wu; Heidi L Weiss; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk
Journal:  Blood       Date:  2008-10-29       Impact factor: 22.113

8.  Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.

Authors:  Ulrike Gerdemann; Anne S Christin; Juan F Vera; Carlos A Ramos; Yuriko Fujita; Hao Liu; Dagmar Dilloo; Helen E Heslop; Malcolm K Brenner; Cliona M Rooney; Ann M Leen
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

9.  Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.

Authors:  Silke Landmeier; Bianca Altvater; Sibylle Pscherer; Heribert Juergens; Lena Varnholt; Anna Hansmeier; Catherine M Bollard; Andreas Moosmann; Guido Bisping; Claudia Rossig
Journal:  J Immunother       Date:  2009-04       Impact factor: 4.456

10.  Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale.

Authors:  Anjum S Kaka; Aaron E Foster; Heidi L Weiss; Cliona M Rooney; Ann M Leen
Journal:  J Immunother       Date:  2008-05       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.